This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Octreotide (Sandostatin, Novartis Pharmaceuticals) is a synthetic octapeptide analog of somatostatin or somatotropin release-inhibiting factor, a regulator of anterior pituitary release. It acts by inhibiting growth hormone, glucagon, and insulin. Octreotide is mainly used for the treatment of gastro-entero-pancreatic neuroendocrine tumors and acromegaly and its neurologic toxicity has been restricted to sleep disturbances, seizures, dizziness, depression, and headache. We here report the first case of dose-dependent reversible parkinsonism and ataxia in a young woman with carcinoid syndrome treated with a high dose of octreotide.
Case report.
This previously healthy 36-year-old woman developed impaired bilateral hand dexterity and overall slowness for about 1 year prior to her neurologic evaluation and 4 years after the initiation of treatment with octreotide and tyramine-restricted diet for carcinoid syndrome, diagnosed during her first pregnancy, at the age of 31 years. Then, she suffered paroxysmal swelling and redness in the upper body, hypoglycemia, and labile blood pressure, which forced an early vaginal delivery. She had been on escalating doses of octreotide, starting at 20 mg IM every 4 weeks and gradually increasing to 40 mg every 3 weeks. Two years prior to her presentation, physical exertion-induced recurrences prompted an additional dose …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
Dr. Kathleen Digre and Dr. Kendra Pham